- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04661280
Donepezil Versus Non-drug Treatment in Alzheimer's Disease. (CHOLINE-2)
Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multicentric, Randomized, Open Study : the CHOLINE-2 Study
Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation.
The aim of this study is to compare the efficiency of the 2 approaches (non-drug versus donepezil) on the symptoms of Alzheimer's disease after 6 months of treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized multicentric open-label study, comparison of 2 therapeutic strategies.
2 arms:
- Standard of care, non-drug approach: following the recommendations of the Alzheimer's disease care by the Frenchh Health Authority. The care is cognitive, psychic, functional or social and centered on the patient and his environment. This care is best carried out by the memory consultations participating in this study and having extensive experience in the care of Alzheimer patients. It is usually based in particular on the prescription of cognitive stimulation sessions by a speech therapist and a mobile Alzheimer specialist team at home for cognitive remediation sessions.
- Donepezil group: Management similar to the previous arm plus addition of Donepezil 5 mg per os once a day for one month and then 10 mg per os once a day until the 6th month.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: DUMURGIER Julien, MD, PhD
- Phone Number: +33140054313
- Email: julien.dumurgier@aphp.fr
Study Contact Backup
- Name: PAQUET Claire, MD, PhD
- Email: claire.paquet@inserm.fr
Study Locations
-
-
-
Paris, France, 75010
- Recruiting
- Cognitive Neurology Center
-
Contact:
- DUMURGIER Julien, MD, PhD
- Phone Number: +33140054313
- Email: julien.dumurgier@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of Alzheimer's disease according to the IWG-2 criteria.
- Age ≥ 50 years.
- Absence of legal protection measures (guardianship, curatorship).
- MMSE score ≥ 10 at inclusion.
- abnormal values for Aβ42 in the CSF or Aβ40 / Aβ42 ratio.
- abnormal values for phosphorylated Tau in CSF
- Presence of a family carer or a person at home who can ensure compliance with treatment if MMSE score <20.
- French native speaker.
Exclusion Criteria:
- Other cause of dementia.
- Previous use of symptomatic treatment for Alzheimer's disease.
- Hypersensitivity to donepezil hydrochloride or to any of the excipients listed in the SPC.
- Cardiological contraindication after possible opinion of a cardiologist, at the initiative of the investigator, in particular bradycardia, sinus disease or other supra-ventricular conduction abnormalities such as sinoatrial or atrioventricular block.
- Taking concomitant medications known to prolong the interval QTc
- Patients at particular risk of ulcer, known ulcer disease or receiving concomitant treatment with non-steroidal anti-inflammatory drugs.
- Patient at risk of urinary retention.
- History of epileptic disease.
- History of neuroleptic malignant syndrome.
- History of asthma or obstructive bronchopulmonary disease.
- Severe hepatic impairment.
Taking one of the following treatments:
- CYP3A4 inhibitors, such as ketonazole.
- 2D6 inhibitors, such as quinidine.
- CYP3A4 inhibitors, such as itraconazole and erythromycin.
- CYP2D6 inhibitors, such as fluoxetine.
- Enzyme inducers such as rifampicin, phenytoin, carbamazepine.
- Antiarrhythmic class IA agents
- Antiarrhythmic class III agents
- other Antipsychotics such as phenothiazine, sertindole, pimozide, ziprasidone.
- some antiobiotics such as clarithromycine, erythromycine, levofloxacine, moxifloxacine.
- Participation in another interventional study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Cognitive remediation
Non-drug treatment, cognitive remediation, cognitive stimulation
|
|
Experimental: Cognitive remediation + Donepezil
Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil
|
Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference of change in the MMSE score
Time Frame: 26 weeks
|
Difference of change in the MMSE score between baseline and 26 weeks in the 2 ams (donepezil versus non-drug).
MMSE is measured at baseline, 6 weeks, 13 weeks, and 26 weeks.
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference of change in the ADAS-Cog scale
Time Frame: 26 weeks
|
Difference of change in the ADAS-Cog scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). ADAS-Cog scale = Alzheimer's Disease Assessment Scale-Cognitive Subscale, scored from 0 to 70 |
26 weeks
|
Difference of change in the CDR scale
Time Frame: 26 weeks
|
Difference of change in the CDR scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). CDR scale = Clinical Dementia Rating, scored from 0 to 3 |
26 weeks
|
Difference of change in the ADL scale
Time Frame: 26 weeks
|
Difference of change in the ADL scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). ADL scale = Autonomy scale on daily activities, scored from 0 to 78 |
26 weeks
|
Difference of change in the quality of life scale
Time Frame: 26 weeks
|
Difference of change in the quality of life scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug).
|
26 weeks
|
Difference of change in the ZARIT scale
Time Frame: 26 weeks
|
Difference of change in the ZARIT scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). ZARIT scale = for assessing caregiver burden, scored from 0 to 88 |
26 weeks
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Donepezil
Other Study ID Numbers
- APHP201183
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease, Early Onset
-
Alnylam PharmaceuticalsRecruitingEarly-Onset Alzheimer DiseaseUnited Kingdom, United States, Netherlands, Canada
-
Mayo ClinicRecruitingEarly Onset Alzheimer DiseaseUnited States
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
ElMindA LtdUnknownDepression | Aging | Mild Cognitive Impairment | Early Onset Alzheimer DiseaseUnited States
-
University of MiamiColumbia University; National Institute on Aging (NIA); Case Western Reserve... and other collaboratorsRecruitingDementia | Mild Cognitive Impairment | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Dementia of Alzheimer TypeUnited States
-
Massachusetts Institute of TechnologyRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Alzheimer'sUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Cairo UniversityNot yet recruitingEarly Disease Onset
-
University of Wisconsin, MadisonRecruiting
Clinical Trials on Donepezil
-
Eisai Inc.Eisai LimitedCompleted
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Samsung Medical CenterEisai Korea Inc.CompletedDementia | Alzheimer's DiseaseKorea, Republic of
-
Corium, Inc.CompletedAlzheimer DiseaseUnited States
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States
-
Eisai Inc.CompletedMigraine HeadacheUnited States
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.Completed